Alzamend Neuro Inc (ALZN) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ALZN Annual Balance Sheets →
Changes in quarterly balance sheet trends offer perspective on how Alzamend Neuro Inc balances growth, leverage, and shareholder equity.
Quarterly Report, GAAP in USD millions
ITEM
(Jul 31 2026)
(Apr 30 2026) (Jan 31 2026) (Oct 31 2025) (Jul 31 2025)
Assets
Cash & cash equivalent7.59
Cash & Short-term Investments7.00
Prepaid Expense And Other Assets Current0.00
Total Current Assets8.25
Equipment/Property/Plant Net0.29
Tax Assets, Noncurrent0.00
Deferred, Prepaid and Other Assets, Noncurrent0.66
Other Assets, Noncurrent0.00
Total Assets8.54
Liabilities
Accounts Payable and Accrued Liabilities, Current LI2.74
Total Current Liabilities2.74
Total Long-term Debt0.00
Accrued Income Taxes, Noncurrent0.00
Total Liabilities2.74
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock76.14
Retained Earnings / Accumulated Deficit-0.03
Other Equity0.00
Common Stockholder's Equity5.80
Preferred Stockholder's Equity0.00
Total Stockholder's Equity5.80
Liabilities & Stockholder's Equity8.54
4 historic quarters locked

Sign in to unlock the full Alzamend Neuro Inc balance sheet history.

About Alzamend Neuro Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q (Period: 20260731)
  • Filed with the SEC: September 10, 2026
  • Source: alz9226210q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001214659-26-011572

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.